Annual ART Provider Cost Estimates for Zimbabwe in 2022

Zimbabwe's 2022 provider costs for antiretroviral therapy totaled $168.66 million for 1.2 million patients, based on a time-driven activity-based costing study across 11 facilities. The dataset includes estimates for adult and pediatric initiation costs, annual maintenance costs, and cost breakdowns for laboratory services and medicines.

Use Cases

• Compare adult ART initiation cost ($57.05) to pediatric initiation cost ($62.70) to analyze resource allocation differences.
• Model projected national costs to $192.44 million by 2026 using current cost trends and patient volume data.
• Analyze cost composition by comparing laboratory services contribution ($30.72) to medicines contribution ($27.98) for adult ART.
• Assess the financial impact of primary care facilities bearing 75% of total costs due to higher patient volume.

Strengths

• Cost estimates are derived from over 2,500 provider-recipient observations collected across 11 facilities.
• Provides specific financial figures, including a total annual cost of $168.66 million for 1.2 million patients.
• Includes validated projections for future costs up to 2026, such as $192.44 million.

Limitations

• The dataset is very small (5.5 KB), indicating limited scope and likely summary-level data without detailed transactional records.
• Represents a single year (2022) for a specific country, limiting temporal and geographic analysis.
• Method relies on estimates and modeling; actual facility-level costs may vary.

Provenance

Source

Juliet Gamuchirai Nyamasve via figshare

Collection Method

Time-driven activity-based costing (TDABC) applied to data from a descriptive cross-sectional study in 11 facilities.

Time Range

2022, with projections to 2026

Freshness

2026-03-25

Geography

Zimbabwe